{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-25-000021","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.287471+00:00","generated_at":"2026-05-16T20:59:41.510205+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SELLAS Q3 net loss $6.8M ($0.06/sh); cash $44.3M plus $29.1M warrant proceeds in Oct","bullets":["Net loss of $6.8M ($0.06 diluted EPS) vs $7.1M ($0.10) a year ago; nine-month loss $19.2M ($0.20).","Cash and equivalents $44.3M at Sep 30, 2025; additional $29.1M net from warrant exercises in October.","Phase 3 REGAL trial of GPS in AML CR2 final analysis expected by year-end 2025 (80 events).","Phase 2 SLS009 in R/R AML data accepted for ASH 2025; trial in first-line AML to start Q1 2026.","R&D expense $4.2M (down 5% YoY); G&A expense $2.9M (down 3% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-25-000021","json":"https://secwatch.observer/filing/0001390478-25-000021.json","markdown":"https://secwatch.observer/filing/0001390478-25-000021.md","text":"https://secwatch.observer/filing/0001390478-25-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047825000021/0001390478-25-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047825000021/sls-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:59:41.510205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}